There are 2137 resources available
615MO - Phase Ib/II study of VERU-111, novel, oral tubulin inhibitor, in men with metastatic castration resistant prostate cancer (mCRPC) who failed an androgen blocking agent
Presenter: Mark Markowski
Session: Mini Oral - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
616MO - Efficacy of BN-brachyury (BNVax) + bintrafusp alfa (BA) + N-803 in castration-resistant prostate cancer (CRPC): Results from a preliminary analysis of the Quick Efficacy Seeking Trial (QuEST1)
Presenter: Jason Redman
Session: Mini Oral - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
617MO - Repurposing metformin as an anticancer drug: Preliminary results of randomized controlled trial in advanced prostate cancer (MANSMED)
Presenter: Reham Alghandour
Session: Mini Oral - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
618MO - Local therapy to the primary tumour for newly diagnosed, oligo-metastatic prostate cancer: A prospective randomized, phase II, open-label trial
Presenter: Bo Dai
Session: Mini Oral - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
1585MO - Factors associated with change in overall survival and quality of life between time of approval and post-marketing among anti-cancer therapies
Presenter: Aida Bujosa Rodríguez
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
1586MO - Pivotal trial endpoints of drugs for rare and non-rare cancers in the US and Europe
Presenter: Kerstin Vokinger
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
1587MO - How much does it cost to research and develop a new medicine? A systematic review and evaluation of 40 years of literature
Presenter: Karla Hernandez Villafuerte
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
1588MO_PR - A comparative study on costs of cancer and access to medicines in Europe
Presenter: Nils Wilking
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
1589MO - Opposition to a patent covering tisagenlecleucel: Using intellectual property (IP) legislation to defend sustainable access to cancer therapies
Presenter: Juliana Veras
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
1590MO - Income loss after a cancer diagnosis from the patient perspective: An analysis based upon the German Socio-Economic Panel (SOEP) survey
Presenter: Diego Hernandez
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast